NanoViricides Inc. (NNVC)

[KMBJN]

It looks like Sanofi's dengue vaccine Dengvaxia (CYD-TDV) was approved just a month or so ago in some Latin American countries (Brazil and Mexico), with projected sales of $1.4B by 2020.

http://www.fiercepharma.com/story/sanofi-gets-first-approval-long-anticipated-vaccine-against-dengue-fever/2015-12-09

https://en.wikipedia.org/wiki/Dengue_vaccine

Looks like a nice vaccine - reduced # of severe dengue cases by 80% in vaccinated children.

"CYD-TDV is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine with those from each of the four dengue serotypes.[2][3] Ongoing phase III trials in Latin America and Asia involve over 31,000 children between the ages of 2 and 14 years. In the first reports from the trials, vaccine efficacy was 56.5% in the Asian study and 64.7% in the Latin American study in patients who received at least one injection of the vaccine.[4][5] Efficacy varied by serotype. In both trials vaccine reduced by about 80% the number of severe dengue cases.[6] An analysis of both the Latin American and Asian studies at the 3rd year of follow-up showed that the efficacy of the vaccine was 65.6% in preventing hospitalization in children older than 9 years of age, but considerably greater (81.9%) for children who were seropositive (indicating previous dengue infection) at baseline.[7] The vaccination series consists of three injections at 0, 6 and 12 months.[3] The vaccine was approved in Mexico, Philippines, and Brazil in December 2015, expected to be the first among the 20 countries in the coming weeks. Tradenamed Dengvaxia, it is approved for use for those aged nine and older and can prevent all four serotypes.[8]"